ArticleiScience2026
Amphiregulin shapes mitochondrial delivery and immune modulation by microvescicles.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amniotic epithelial cells (AECs) exert potent paracrine immunoregulatory functions, yet whether inflammatory cues enhance the biological activity of their extracellular vesicles (EVs) remains unclear. To address this question, we characterized the secretome of ovine AECs under basal and lipopolysaccharide (LPS)-stimulated conditions using label-free proteomics and genetic approaches. Inflammatory stimulation profoundly remodeled the microvesicles (MVs) cargo, enriching 101 proteins associated with metabolic and regulatory pathways. Among the top 5% were two immune-related proteins, including amphiregulin (AREG), an epidermal growth factor receptor ligand involved in immune regulation and tissue remodeling. AREG silencing reduced AREG-positive MVs and was associated with altered mitochondrial cargo content and transfer to immune cells. Consequently, siAREG-MVs showed reduced uptake by PBMCs and T cells, resulting in diminished suppression of proliferation and CD3-dependent NFAT activation. Exogenous AREG partially restored these functions. Collectively, these findings identify inflammation-driven AREG signaling as a key mechanism enhancing the immunomodulatory potential of AEC-derived MVs for cell-free immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.